DE60000003D1 - Paroxetinmethansulfonat - Google Patents

Paroxetinmethansulfonat

Info

Publication number
DE60000003D1
DE60000003D1 DE60000003T DE60000003T DE60000003D1 DE 60000003 D1 DE60000003 D1 DE 60000003D1 DE 60000003 T DE60000003 T DE 60000003T DE 60000003 T DE60000003 T DE 60000003T DE 60000003 D1 DE60000003 D1 DE 60000003D1
Authority
DE
Germany
Prior art keywords
paroxetine methanesulfonate
paroxetine
methanesulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60000003T
Other languages
English (en)
Other versions
DE60000003T2 (de
Inventor
Andrew Simon Craig
Victor W Jacewicz
David Alan Jones
Deirdre O'keeffe
Michael Urquhart
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60000003(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60000003D1 publication Critical patent/DE60000003D1/de
Application granted granted Critical
Publication of DE60000003T2 publication Critical patent/DE60000003T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60000003T 1998-07-02 2000-04-10 Paroxetinmethansulfonat Revoked DE60000003T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (2)

Publication Number Publication Date
DE60000003D1 true DE60000003D1 (de) 2001-08-09
DE60000003T2 DE60000003T2 (de) 2002-03-21

Family

ID=27269380

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69911774T Expired - Fee Related DE69911774T2 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat-acetonitrilsolvat 1:1
DE69900007T Revoked DE69900007T2 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat
DE29907248U Expired - Lifetime DE29907248U1 (de) 1998-07-02 1999-04-23 Neue Verbindung
DE19918588A Ceased DE19918588A1 (de) 1998-07-02 1999-04-23 Piperidinverbindung
DE60000003T Revoked DE60000003T2 (de) 1998-07-02 2000-04-10 Paroxetinmethansulfonat

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE69911774T Expired - Fee Related DE69911774T2 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat-acetonitrilsolvat 1:1
DE69900007T Revoked DE69900007T2 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat
DE29907248U Expired - Lifetime DE29907248U1 (de) 1998-07-02 1999-04-23 Neue Verbindung
DE19918588A Ceased DE19918588A1 (de) 1998-07-02 1999-04-23 Piperidinverbindung

Country Status (34)

Country Link
US (4) US6063927A (de)
EP (5) EP0970955B1 (de)
JP (1) JP2002519422A (de)
KR (1) KR20010053336A (de)
CN (1) CN1127502C (de)
AR (2) AR011759A1 (de)
AT (4) ATE251155T1 (de)
AU (4) AU713877B3 (de)
BE (3) BE1012403A5 (de)
BR (1) BR9911682A (de)
CA (1) CA2269999A1 (de)
CH (1) CH689805A8 (de)
DE (5) DE69911774T2 (de)
DK (7) DK199900176U3 (de)
ES (4) ES2209428T3 (de)
FI (2) FI4209U1 (de)
FR (2) FR2780728B1 (de)
GB (5) GB2339428A (de)
GR (3) GR990100140A (de)
HU (1) HUP0102334A3 (de)
IE (5) IE20000633A1 (de)
IL (1) IL140628A (de)
IT (1) IT1312540B1 (de)
LU (1) LU90388B1 (de)
NL (4) NL1011875C2 (de)
NO (1) NO319030B1 (de)
NZ (1) NZ509180A (de)
PL (1) PL345214A1 (de)
PT (4) PT1089996E (de)
SE (1) SE9901462A0 (de)
SI (3) SI1089996T1 (de)
SK (1) SK20262000A3 (de)
TR (1) TR200100054T2 (de)
WO (1) WO2000001694A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
WO1998037938A1 (en) * 1997-02-27 1998-09-03 Ajinomoto Co., Inc. Crystallization apparatus and crystallization method
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
HUP0303827A2 (hu) * 2000-08-28 2004-04-28 Synthon B.V. Paroxetinkészítmények és eljárások ezek előállítására
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1874908B1 (de) 2005-04-07 2014-06-11 Xy, Llc Methode zur Reduktion von Mikroorganismen in einem Durchflussweg unter Verwendung von Diacetonalkohol
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
CA2679484A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2,5-dione
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (de) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
EP0223334B1 (de) * 1985-08-10 1991-07-10 Beecham Group Plc Verfahren zur Herstellung von Arylpiperidincarbinol
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
NZ307479A (en) * 1995-05-17 1999-08-30 Novo Nordisk As A process for preparing 4-(4-halo substituted phenyl)-3-(3,4-methylenedioxy phenoxy methyl)piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (de) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Verfahren zur Trocknung von Paroxetinhydrochlorid
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
KR20010040711A (ko) * 1998-02-06 2001-05-15 피터 기딩스 파록세틴의 염
BR9908825A (pt) * 1998-03-16 2000-11-21 Smithkline Beecham Plc Forma cristalina de paroxetina
JP2002511466A (ja) * 1998-04-09 2002-04-16 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー マレイン酸パロキセチン
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
NO991944D0 (no) 1999-04-23
HUP0102334A2 (hu) 2002-05-29
FI990922A0 (fi) 1999-04-23
EP1020463A1 (de) 2000-07-19
DE69900007D1 (de) 2000-09-07
IL140628A (en) 2004-06-20
SK20262000A3 (sk) 2001-07-10
ITMI990866A1 (it) 2000-10-23
DK1089996T3 (da) 2004-02-09
EP1089996A1 (de) 2001-04-11
BE1011664A6 (fr) 1999-11-09
CN1127502C (zh) 2003-11-12
DK200000390U1 (da) 2000-12-27
DK199900234U4 (da) 2000-12-22
ES2158778B1 (es) 2002-03-16
GB2352395B (en) 2004-02-11
ES2158778A1 (es) 2001-09-01
DE69900007T2 (de) 2001-06-07
FI4209U1 (fi) 1999-11-10
NL1012271C2 (nl) 1999-09-23
ATE195121T1 (de) 2000-08-15
DE29907248U1 (de) 1999-09-09
SI1020464T1 (en) 2001-12-31
AR018197A1 (es) 2001-10-31
EP0970955A1 (de) 2000-01-12
SI1089996T1 (en) 2004-04-30
CA2269999A1 (en) 2000-01-02
EP1020464A1 (de) 2000-07-19
CH689805A8 (fr) 2000-02-29
LU90388B1 (fr) 2001-01-29
SE9901462D0 (sv) 1999-04-23
GB2336364B (en) 2000-05-10
NL1011875A1 (nl) 2000-01-07
DE60000003T2 (de) 2002-03-21
GB0026487D0 (en) 2000-12-13
DK199900234U1 (da) 2000-12-22
TR200100054T2 (tr) 2001-06-21
AU3619199A (en) 2000-01-24
ES2209428T3 (es) 2004-06-16
FR2802098A1 (fr) 2001-06-15
JP2002519422A (ja) 2002-07-02
FIU990190U0 (fi) 1999-04-23
GB2352395A (en) 2001-01-31
ES2149044T3 (es) 2000-10-16
AU732211C (en) 2004-05-06
EP0970955B1 (de) 2000-08-02
EP1020464B1 (de) 2001-07-04
SE9901462L (de)
GR990100140A (el) 2000-03-31
GR3034328T3 (en) 2000-12-29
PT102291A (pt) 2000-05-31
AU2392899A (en) 2000-01-20
GR1003350B (el) 2000-03-29
DE19918588A1 (de) 2000-01-27
GB2367003A (en) 2002-03-27
NL1011875C2 (nl) 2000-03-24
AT3185U2 (de) 1999-11-25
GB2377637A (en) 2003-01-22
GB2336364A (en) 1999-10-20
IE20000633A1 (en) 2001-10-17
US20020035130A1 (en) 2002-03-21
CN1315949A (zh) 2001-10-03
AU713877B3 (en) 1999-12-09
CH689805A5 (fr) 1999-11-30
AR011759A1 (es) 2000-09-13
ATE202777T1 (de) 2001-07-15
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
WO2000001694A1 (en) 2000-01-13
ES2157881T3 (es) 2001-09-01
BE1012403A5 (fr) 2000-10-03
SE9901462A0 (sv) 2000-01-03
PT970955E (pt) 2000-11-30
HK1037877A1 (en) 2002-02-22
BE1012420A6 (fr) 2000-10-03
IES20000893A2 (en) 2001-05-30
FI990922L (fi) 2000-01-03
FR2780728B1 (fr) 2001-02-16
PL345214A1 (en) 2001-12-03
AU732211B2 (en) 2001-04-12
KR20010053336A (ko) 2001-06-25
NZ509180A (en) 2001-06-29
NL1011874C1 (nl) 1999-07-12
ATE251155T1 (de) 2003-10-15
DK199900176U3 (da) 1999-08-13
DK0970955T3 (da) 2000-10-09
GB9920332D0 (en) 1999-11-03
IES20000894A2 (en) 2001-05-30
GB9909505D0 (en) 1999-06-23
NL1012272C1 (nl) 1999-07-12
AU713131B3 (en) 1999-11-25
BR9911682A (pt) 2001-12-26
GB2339428A (en) 2000-01-26
IT1312540B1 (it) 2002-04-22
AT3185U3 (de) 2000-01-25
FI112077B (fi) 2003-10-31
IES990343A2 (en) 2000-01-02
EP1288214A1 (de) 2003-03-05
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
DK199900554A (da) 2000-01-03
US6063927A (en) 2000-05-16
FR2780728A1 (fr) 2000-01-07
PT102291B (pt) 2002-07-31
GR3036208T3 (en) 2001-10-31
EP1089996B1 (de) 2003-10-01
NO319030B1 (no) 2005-06-06
DK1020464T3 (da) 2001-09-24
SI0970955T1 (en) 2001-02-28
US20010023253A1 (en) 2001-09-20
IES81166B2 (en) 2000-05-31
PT1020464E (pt) 2001-10-30
HUP0102334A3 (en) 2003-12-29
US20020193406A1 (en) 2002-12-19
IE990344A1 (en) 2000-05-03
NO991944L (no) 2000-01-03
DE69911774T2 (de) 2004-08-05
DE69911774D1 (de) 2003-11-06
IL140628A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
ATE195121T1 (de) Paroxetinmethansulfonat
ATE341990T1 (de) Sigmidoskop
DE59902874D1 (de) Buchsenkontakt
DE59901560D1 (de) Retrograder tibianagel
NO992430D0 (no) R°rkobling
NO992198D0 (no) R°rledningspigg
ID23761A (id) Trisiklik tersubstitusi
EP1124578A4 (de) Neuartige immunadjuvanzien
ATE262513T1 (de) Benzoylpyridazine
ID23219A (id) Trisiklik tersubstitusi
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59808995D1 (de) Endomikroskopsystem
DE59807217D1 (de) Nadellager
DE19842103B4 (de) Stanznietzuführung
DE59911610D1 (de) Substituierte benzoylcyclohexandione
DE59903616D1 (de) Rollenwicklerwalze
DE59902088D1 (de) Achrathermer Reimager
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
DE59912188D1 (de) Substituierte phenyluracile
ATE303996T1 (de) Substituierte acylaminophenyl-uracile
NO20005325D0 (no) Bjelkelagskonstruksjon
DE59901263D1 (de) Einzelplatz-sortierer
ATA126298A (de) Verpuffungsklappe
NO983018D0 (no) R°ranordning

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation